Literature DB >> 15957971

Economic assessment on the management of chronic lymphocytic leukaemia.

Kim M Goor1, M Ronald Schaafsma, Peter C Huijgens, Michel van Agthoven.   

Abstract

In the last decade, several new promising treatments for chronic lymphocytic leukaemia (CLL) have been developed. Healthcare costs are increasing and new treatments tend to be very expensive; therefore, information about the cost effectiveness in treatments for CLL is urgently needed. The authors performed a literature review on the currently available economic evaluations on CLL treatments. A total of 65 articles were found, of which 11 could be included. These articles were evaluated on the basis of six methodological requirements for economic evaluations, enabling readers to judge the value of the studies. Only a small amount of information was available on the costs of CLL treatments. Future economic evaluations should be performed according to the methodological requirements for these studies, which should also be properly documented.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15957971     DOI: 10.1517/14656566.6.7.1179

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

Review 1.  Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature.

Authors:  Simon Frey; Carl R Blankart; Tom Stargardt
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

2.  Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis.

Authors:  Thitima Kongnakorn; James A Sterchele; Christopher G Salvador; Denis Getsios; Mkaya Mwamburi
Journal:  Clinicoecon Outcomes Res       Date:  2014-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.